A5076770614- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Bacteriophages and microbial interactions
- Cancer-related gene regulation
- Chronic Lymphocytic Leukemia Research
- Biochemical and Molecular Research
- SARS-CoV-2 and COVID-19 Research
- Lung Cancer Treatments and Mutations
- RNA and protein synthesis mechanisms
- Inflammasome and immune disorders
- Microbial Natural Products and Biosynthesis
- Redox biology and oxidative stress
- Fungal Infections and Studies
- Hepatitis B Virus Studies
- Antifungal resistance and susceptibility
- Advanced Glycation End Products research
- interferon and immune responses
- Bacterial Genetics and Biotechnology
- RNA modifications and cancer
- Glycosylation and Glycoproteins Research
- Heme Oxygenase-1 and Carbon Monoxide
- Hippo pathway signaling and YAP/TAZ
- vaccines and immunoinformatics approaches
- Flavonoids in Medical Research
- Ubiquitin and proteasome pathways
Yonsei University
2018-2023
The bacterial effector proteins SseK and NleB glycosylate host on arginine residues, leading to reduced NF-κB-dependent responses infection. Salmonella SseK1 SseK2 are E. coli NleB1 orthologs that behave as NleB1-like GTs, although they differ in protein substrate specificity. Here we report these enzymes retaining glycosyltransferases composed of a helix-loop-helix (HLH) domain, lid catalytic domain. A conserved HEN motif (His-Glu-Asn) the active site is important for enzyme catalysis...
Rapid emergence of new variants severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has prompted an urgent need for the development broadly applicable and potently neutralizing antibody platform against SARS-CoV-2, which can be used combatting disease 2019 (COVID-19). In this study, based on a noncompeting pair phage display-derived human monoclonal antibodies (mAbs) specific to receptor-binding domain (RBD) SARS-CoV-2 isolated from synthetic library, we generated K202.B, novel...
In the Hippo signaling pathway, palmitoylated transcriptional enhanced associated domain (TEAD) protein interacts with coactivator Yes-associated protein/PDZ-binding motif, leading to upregulation of oncogenes such as Ctgf and Cyr61. Consequently, targeting palmitoylation sites TEAD has emerged a promising strategy for treating TEAD-dependent cancers. Compound
Abstract ErbB3, a member of the ErbB receptor family, is potent mediator in development and progression cancer, its activation plays pivotal roles acquired resistance against anti-EGFR therapies other standard-of-care therapies. Upon ligand (NRG1) binding, ErbB3 forms heterodimers with proteins (i.e., EGFR ErbB2), which allows downstream PI3K/Akt signaling. In this study, we developed fully human anti-ErbB3 antibody, named ISU104, as an anticancer agent. ISU104 binds potently specifically to...
Inflammasomes are multi-protein complexes and play a crucial role in host defense against pathogens. Downstream inflammatory responses through inflammasomes known to be related the oligomerization degree of ASC specks, but detailed mechanism still remains unexplored. Here, we demonstrate that degrees specks regulate caspase-1 activation extracellular space. A protein binder specific for pyrin domain (PYD) (ASC
Yeast Rpf2 plays a critical role in the incorporation of 5S rRNA into pre-ribosomes by forming binary complex with Rrs1. The protein characteristics and overexpression phenotypes Arabidopsis Ribosome Production Factor 2 (ARPF2) Regulator Synthesis 1 (ARRS1) have been previously studied. Here, we analyze loss-of-function ARPF2 ARRS1 using virus-induced gene silencing to determine their functions pre-rRNA processing ribosome biogenesis. led pleiotropic developmental defects. RNA gel blot...
Glycosylation is one form of protein modification and plays a key role in stability, function, signaling regulation even cancer. NleB SseK are bacterial effector proteins possess glycosyltransferase activity, though they have different substrate preferences. NleB/SseKs transfer the GlcNAc sugar to an arginine residue host proteins, leading reduced NF-κB-dependent responses. By combining X-ray crystallography, NMR, molecular dynamics, enzyme kinetic assays vivo experiments, we demonstrated...
Abstract CK2α is a constitutively active and highly conserved serine/threonine protein kinase that involved in the regulation of key cellular metabolic pathways associated with variety tumours cancers. The most well-known inhibitor human clinical trial candidate CX-4945, which has recently shown to exhibit not only anti-cancer, but also anti-fungal properties. This prompted us work on orthologue, Cka1, from pathogenic fungus Cryptococcus neoformans , causes life-threatening systemic...
Cancer targeting nanoparticles have been extensively studied, but stable and applicable agents yet to be developed. Here, we report based on hepatitis B core antigen (HBcAg) for cancer therapy. HBcAg monomers assemble into spherical capsids of 180 or 240 subunits. was engineered present an affibody binding human epidermal growth factor receptor 1 (EGFR) histidine tyrosine tags gold ions. The (HAF) bound specifically EGFR exterminated the EGFR-overexpressing adenocarcinomas under alternating...
<p>Figure S1-S6, Table S1-S7</p>
<p>Figure S1-S6, Table S1-S7</p>
<div>Abstract<p>ErbB3, a member of the ErbB receptor family, is potent mediator in development and progression cancer, its activation plays pivotal roles acquired resistance against anti-EGFR therapies other standard-of-care therapies. Upon ligand (NRG1) binding, ErbB3 forms heterodimers with proteins (i.e., EGFR ErbB2), which allows downstream PI3K/Akt signaling. In this study, we developed fully human anti-ErbB3 antibody, named ISU104, as an anticancer agent. ISU104 binds...
<div>Abstract<p>ErbB3, a member of the ErbB receptor family, is potent mediator in development and progression cancer, its activation plays pivotal roles acquired resistance against anti-EGFR therapies other standard-of-care therapies. Upon ligand (NRG1) binding, ErbB3 forms heterodimers with proteins (i.e., EGFR ErbB2), which allows downstream PI3K/Akt signaling. In this study, we developed fully human anti-ErbB3 antibody, named ISU104, as an anticancer agent. ISU104 binds...